Product Description
Mechanisms of Action: VEGFA Blocker
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colorectal Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BP29889 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2019-10-30 |
21% |
BP29889 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2019-10-30 |
21% |
BP28179 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2016-12-02 |
41% |
McCAVE | P2 |
Terminated |
Colorectal Cancer |
2016-07-29 |